Emulfree Duo

Tefose® 1500 (mixture of PEG-6 stearate and PEG-32 stearate) is a  nonionic oil-in-water emulsifier for topical formulations that provides high stability in topical fluid lotions and light emulsions over a wide pH range.

Tefose® 63  (mixture of PEG-6 stearate and ethylene glycol palmitostearate and PEG-32 stearate) is a nonionic oil-in-water emulsifier for topical formulations.  It delivers high stability for a wide range of APIs in emulsions. Widely used in vaginal creams due to high mucosal tolerance.
...

Transcutol® HP (diethylene glycol monoethyl ether) is the highest-purity grade solvent and solubilizer for solubility and bioavailability enhancement for oral and alternative routes (parenteral, nasal, ophthalmic formulations).

Transcutol® P (D=diethylene glycol monoethyl ether) a high-purity solvent and powerful solubilizer associated with skin penetration enhancement in topical dosage forms.

Transcutol® V (diethylene glycol monoethyl ether) is a high-purity solvent for oral, topical (spot-on, pour-on) and parenteral veterinary medicines. No Maximum Residue Limit for use in food-producing animals.

Labrafac™ MC60 (glycerol monocaprylocaprate) is a water-insoluble surfactant used in oral lipid-based formulation for bioavailability enhancement of poorly water-soluble, and poorly permeable drugs. It acts as a solubilizer and as an intestinal permeation enhancer.

Gelucire® 59/14 is a mixture of lauroyl PEG-32 glycerides and PEG 6000 and has surfactant properties. It is a self-emulsifying excipient used for oral bioavailability enhancement of poorly water-soluble drugs, thanks to its high solubilizing capacity.

Capryol 90 (propylene glycol monocaprylate) is a nonionic water-insoluble surfactant used as cosurfactant in oral lipid-based formulation SEDDS and SMEDDS. Cosurfactant and solubilizer in topical dosage forms.

Maisine® CC (glyceryl monolinoleate) is an oil composed of long-chain mono-, di-, and triglycerides for lipid-based formulations to solubilize and increase oral bioavailability of poorly water-soluble lipophilic APIs. Used in self-emulsifying lipid formulations (SEDDS and SMEDDS) as an oily vehicle. Its hi...

Compritol® 888 ATO (glyceryl dibehenate) is a glyceride with a high melting point used as a modified release agent or lubricant in tablets. Can also be used in lipid coating technologies and as lipid carrier for nanoparticles.

Compritol® 888 Pellets (glyceryl dibehenate) is a glyceride with a high melting point used as consistency agent in topical formulations.

Compritol® E ATO (for nutraceuticals) is a high melting point lipid obtained by the esterification of glycerin with C22 fatty acid, conforming to food additive status. The powder form is used as a modified release agent or lubricant for high-dose nutraceutical tablets.
PALM OIL FREE version a...

Discover Gelucire® 59/14, an add-on in Gattefossé Gelucire® range, for oral bioavailability enhancement

Selecting best excipient

Discover Labrafac™ MC60, glycerol monocaprylocaprate, an oral bioavailability enhancer.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. Patient adherence to skin treatments Bi-gels: formulating new topical drugs Emulfree® Duo, a ready-to-use excipient designed to make bi-gels Case studies

Discover our brand new excipient Emulfree® Duo, a ready-to-use stabilizing agent, enabler of bi-gel, an emerging topical dosage form.

This session was originally broadcast as part of the CPHI Worldwide 2021 digital content programme. This session explores: Using Lipid-based formulations to address oral bioavailability issues Labrafac™ MC60, glycerol monocaprylocaprate, Gattefossé new bioehancer Case study: step-by-step development of a lipid-based formulation of dutasteride with Labrafac™ MC60 Gattefossé technical expertise

Many drugs exhibit poor solubility and/or permeability leading to weak oral bioavailability. To overcome these issues, different technologies have been developed. Among them, lipid-based formulation (LBF) is an option worth considering as it can be used from the very beginning of drug development to product, reducing time to market.